Literature DB >> 22494199

Recirculation usually precedes malignant edema in middle cerebral artery infarcts.

T H Nielsen1, N Ståhl, W Schalén, P Reinstrup, P Toft, C H Nordström.   

Abstract

OBJECTIVES: In patients with large middle cerebral artery (MCA) infarcts, maximum brain swelling leading to cerebral herniation and death usually occurs 2-5 days after onset of stroke. The study aimed at exploring the pattern of compounds related to cerebral energy metabolism in infarcted brain tissue.
METHODS: Forty-four patients with malignant MCA infarcts were included after decision to perform decompressive hemicraniectomy (DHC). Cerebral energy metabolism was in all patients monitored bedside by 1-3 microdialysis catheters inserted into the infarcted hemisphere during DHC. In 29 of the patients, one microdialysis catheter was also placed in the non-infarcted hemisphere. MCA blood-flow velocity was monitored bilaterally by transcranial Doppler ultrasound.
RESULTS: The interstitial glucose levels were in both sides within normal limits throughout the monitoring period. Mean lactate/pyruvate (LP) ratio was very high in infarcted tissue immediately after DHC. The ratio slowly decreased but did not reach normal level during the study period. In the infarcted hemisphere, MCA blood-flow velocities increased from approximately 42 cm/s 1 day prior to DHC (nine of nine patients) to approximately 60 cm/s at day 4.
CONCLUSIONS: Normal interstitial glucose level in the infarcted hemisphere in combination with substantial MCA blood-flow velocities bilaterally even before DHC was performed indicates that malignant brain swelling usually commences when the embolus/thrombosis has been largely resolved and recirculation of the infarcted area has started. The protracted increase of the LP ratio in infarcted tissue might indicate mitochondrial dysfunction.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22494199     DOI: 10.1111/j.1600-0404.2012.01664.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

1.  Asymmetric TCD Findings in Malignant MCA Infarction, Resolution after Decompressive Hemicraniectomy: A Case Report.

Authors:  Hazel Gaile Barrozo; Maria Anna De Guzman; Jose Navarro; Narayanaswamy Venketasubramanian
Journal:  Case Rep Neurol       Date:  2020-12-14

2.  Bedside diagnosis of mitochondrial dysfunction after malignant middle cerebral artery infarction.

Authors:  T H Nielsen; W Schalén; N Ståhl; P Toft; P Reinstrup; C H Nordström
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

3.  Antagonists of the Vasopressin V1 Receptor and of the β(1)-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes - but the Mechanisms Differ.

Authors:  Leif Hertz; Junnan Xu; Ye Chen; Marie E Gibbs; Ting Du; Leif Hertz; Junnan Xu; Ye Chen; Marie E Gibbs; Ting Du
Journal:  Curr Neuropharmacol       Date:  2014-07       Impact factor: 7.363

4.  Paradoxical association of symptomatic cerebral edema with local hypoperfusion caused by the 'watershed shift' after revascularization surgery for adult moyamoya disease: a case report.

Authors:  Jin Yu; Miao Hu; Lei Yi; Keyao Zhou; Jianjian Zhang; Jincao Chen
Journal:  Ther Adv Neurol Disord       Date:  2019-09-25       Impact factor: 6.570

Review 5.  Bedside interpretation of cerebral energy metabolism utilizing microdialysis in neurosurgical and general intensive care.

Authors:  Carl-Henrik Nordström; Axel Forsse; Rasmus Peter Jakobsen; Simon Mölström; Troels Halfeldt Nielsen; Palle Toft; Urban Ungerstedt
Journal:  Front Neurol       Date:  2022-08-10       Impact factor: 4.086

Review 6.  Need for a Paradigm Shift in the Treatment of Ischemic Stroke: The Blood-Brain Barrier.

Authors:  Maria Luz Alonso-Alonso; Ana Sampedro-Viana; Sabela Fernández-Rodicio; Marcos Bazarra-Barreiros; Alberto Ouro; Tomás Sobrino; Francisco Campos; José Castillo; Pablo Hervella; Ramón Iglesias-Rey
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.